Neurogene price to book ratio NGNE

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026: 2.2×
10-year median: 1.7×
Against its 10-year history: 57th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.2× to 7.7×
Peer median: 1.9×

Neurogene's price to book ratio is 2.2× as of Oct 23, 2026.

That is above its ten-year median of 1.7×, close to the middle of its last ten years.

Over that time it ranged from 0.2× in Dec 2022 to 7.7× in Feb 2020.

The median for 10 large drugmakers of a similar size is 1.9×.

Price to book ratio over time

median 1.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.2×	1.0×	3.6×
2025	1.2×	0.4×	2.5×
2024	2.5×	0.7×	5.7×
2023	0.6×	0.2×	0.6×
2022	0.2×	0.2×	1.1×
2021	1.3×	1.3×	2.9×
2020	2.9×	1.8×	7.7×
2019	7.0×	0.7×	7.0×
2018	0.6×	0.6×	4.2×
2017	2.4×	2.2×	2.9×
2016	2.5×	1.1×	2.8×
2015	1.9×	0.5×	9.2×
2014	1.6×	1.2×	2.0×

Against its peers

Companies in Drug Manufacturers - General nearest Neurogene's size, closest first, today.

Company	Price to book ratio
NGNENeurogene	2.2×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	2.4×
ABUSArbutus Biopharma	3.2×
NATRNatures Sunshine Products	1.3×
AMPHAmphastar Pharmaceuticals	1.4×
OMEROmeros	n/m
Peer median	1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Neurogene

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.